In the latest example of the invasion of technology into the Automotive Industry, the Consumer Electronics Association (CEA) announced that “a record nine automotive manufacturers will exhibit at the upcoming 2014 International CES [Consumer Electronics Show] ®”. As the Dashboard has reported on before, all things technology driven are seeping into the Automotive Industry. It is easier at this point to identify which OEM’s are not going to be at 2014 International CES.
Multiple education sessions dedicated to the Automotive Industry will take place at the CES. As the CES press release details:
- Just Around the Bend: How Technology will Change Driving: The dashboard revolution is heating up and the road to self-driving cars is lined with technology we couldn’t have imagined 10 years ago. From safe-driving sensors to voice and gesture controlled infotainment systems to heads-up displays with augmented-reality overlays and more. Gurus of car tech reveal which technologies are redefining driving’s future.
- Connect2Car: If You’re Not Connecting, You’re Interrupting: Connected vehicles are quickly becoming part of the contemporary driving experience. Technologies and innovations are emerging from both automotive and consumer electronics companies, as well as aftermarket and new, non-endemic players. The challenge remains on how effectively systems, apps, content and context get installed, upgraded and integrated into vehicles and consumer lifestyles.
- Collaborate Or Die: Once carmakers demanded their suppliers “open the box” of in-vehicle infotainment “head units,” the way IVI software is developed has changed completely. Formerly bitter rivals now must work together on the increasing complex IVI infrastructure while still maintaining their competitive advantage. This session will focus on the alliances and other collaborative efforts facilitating these next generation systems.
This is just the latest example how the trend of Advanced Manufacturing is taking over the legal world. Get on board, or get left behind.
Disclaimer
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.
Related Insights
23 December 2024
Labor & Employment Law Perspectives
Regulating Artificial Intelligence in Employment Decision-Making: What’s on the Horizon for 2025
Share on TwitterShare by EmailShareBack to topEmployment law in 2024 could aptly be summarized as the “Year of Artificial Intelligence Legislation.
23 December 2024
Health Care Law Today
Medicare Telehealth Flexibilities Get a Three-Month Lifeline
Share on TwitterShare by EmailShareBack to topAfter much uncertainty, Congress has extended many Medicare telehealth flexibilities through March 31, 2025, in its end-of-year appropriations bill.
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.